DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells

Cancer Letters

Volumn 252, Issue 2, 2007, Pages 270-279

  Poljaková, Jitka ^a   Frei, Eva ^b   Gomez, Jacobo E ^b   Aimová, Dagmar ^a   Eckschlager, Tomáš ^a   Hraběta, Jan ^a   Stiborová, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytochromes P450; DNA adduct; Ellipticine; Human leukemia HL 60 and CCRF CEM cells; Peroxidases

Indexed keywords

CYTOCHROME P450; ELLIPTICINE; MYELOPEROXIDASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA ADDUCTS; ELLIPTICINES; HUMANS; LEUKEMIA;

EID: 34248662505     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.037     Document Type: Article

References (27)

1. Stiborová M., Bieler C.A., Wiessler M., and Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 62 (2001) 675-684
2. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch. Biochem. Biophys. 259 (1987) 1-14
3. Singh M.P., Hill G.C., Peoch D., Rayner B., Inabach J.L., and Lown J.W. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33 (1994) 1085-10271
4. Chu Y., and Hsu M.T. Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res. 20 (1992) 4033-4038
5. Monnot M., Mauffret O., Simon V., Lescot E., Psaume B., Saucier J.M., Charra M., Belehradek Jr. J., and Fermandjian S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. 25 (1991) 1820-1829
6. Fossé P., René B., Charra M., Paoletti C., and Saucier J.M. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol. Pharmacol. 42 (1992) 590-595
7. Froelich-Ammon S.J., Patchan M.W., Osheroff N., and Thompson R.B. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 270 (1995) 14998-15004
8. Ohashi M., Sugikawa E., and Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn. J. Cancer Res. 86 (1995) 819-829
9. Sugikawa E., Hosoi T., Yazaki N., Gamanuma N., Nakanishi N., and Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 19 (1999) 3099-3108
10. Schwaller M.A., Allard B., Lescot E., and Moreau F. Protonophoric activity of ellipticine and isomers across the energy-transducing membrane of mitochondria. J. Biol. Chem. 270 (1995) 22709-22713
11. Stiborová M., Stiborová-Rupertová M., Bořek-Dohalská L., Wiessler M., and Frei E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 16 (2003) 38-47
12. Stiborová M., Poljaková J., Ryšlavá H., Drači{dotless}́nský M., Eckschlager T., and Frei E. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int. J. Cancer 120 (2007) 243-251
13. Poljaková J., Drači{dotless}́nský M., Frei E., Hudeček J., and Stiborová M. The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect. Czech. Chem. Commun. 71 (2006) 1169-1185
14. Bořek-Dohalská L., Frei E., and Stiborová M. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect. Czech. Chem. Commun. 69 (2004) 603-615
15. Frei E., Bieler C.A., Arlt V.M., Wiessler M., and Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem. Pharmacol. 64 (2002) 289-295
16. 32P-postlabeling. Int. J. Cancer 107 (2003) 885-890
17. 2-oxide. Cancer Res. 64 (2004) 8374-8380
18. Poljaková J., Forsterová K., Šulc M., Frei E., and Stiborová M. Oxidation of ellipticine by peroxidases. Biomed. Pap. 149 (2005) 449-453
19. Cinatl Jr. J., Cinatl J., Driever P.H., Kotchetkov R., Pouckova P., Kornhuber B., and Schwabe D. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-cancer Drugs 8 (1997) 958-963
20. Stiborová M., Marti{dotless}́nek V., Rýdlová H., Hodek P., and Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 62 (2002) 5678-5684
21. Yasukochi Y., Peterson J.A., and Masters B. NADPH-cytochrome c (P450) reductase: spectrophotometric and stopped flow kinetic studies on the formation of reduced flavoprotein intermediates. J. Biol. Chem. 254 (1979) 7097-7104
22. Stiborová M., Marti{dotless}́nek V., Rýdlová H., Koblas T., and Hodek P. Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 220 (2005) 145-154
23. Lanza F., Latorraca A., Moretti S., Castagnari B., Ferrari L., and Castoldi G. Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. Cytometry 30 (1997) 34-144
24. Anagnostopoulos A.K., Vougas K., Kolialexi A., Mavrou A., Fountoulakis M., and Tsangaris G.T. The protein profile of the human immature T-cell line CCRF-CEM. Cancer Genomics & Proteomics 2 (2005) 271-300
25. DeMarini D.M., Abu-Shakra A., Gupta R., Hendee L.J., and Levine J.G. Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98. Environ. Mol. Mutagenesis 20 (1992) 12-18
26. Rekha G.K., and Sladek N.E. Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother. Pharmacol. 40 (1997) 215-224
27. Ivy S.P., Tulpule A., Fairchild C.R., Averbuch S.D., Myers C.E., Nebert D.W., Baird W.M., and Cowan K.H. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J. Biol. Chem. 26 (1988) 19119-19125